Atenolol

Indications
Oral
Hypertension
Adult: 25-100 mg daily as a single dose, depending on response. Takes 1-2 wk for full effect to be observed.
CrCl (ml/min)Dosage Recommendation
15-3550 mg daily.
<1525 mg daily or 50 mg on alternate days.
Dialysis25-50 mg after each dialysis.

Oral
Angina pectoris
Adult: 50-100 mg daily given as single or divided doses. Max dose: 200 mg daily.
CrCl (ml/min)Dosage Recommendation
15-3550 mg daily.
<1525 mg daily or 50 mg on alternate days.
Dialysis25-50 mg after each dialysis.

Oral
Prophylaxis of migraine
Adult: 50-100 mg daily.
CrCl (ml/min)Dosage Recommendation
15-3550 mg daily.
<1525 mg daily or 50 mg on alternate days.
Dialysis25-50 mg after each dialysis.

Intravenous
Emergency treatment of cardiac arrhythmias
Adult: 2.5 mg injected at a rate of 1 mg/minute, may repeat every 5 minutes if needed. Max: 10 mg. Alternatively, 150 mcg/kg to be infused over 20 minutes. May repeat Inj or infusion procedure every 12 hr as needed. Once control is achieved, maintain with oral doses of 50-100 mg/day.
CrCl (ml/min)Dosage Recommendation
15-3510 mg once every 2 days.
<1510 mg once every 4 days.

Intravenous
Acute myocardial infarction
Adult: To be given within 12 hr of the onset of chest pain. Inject 5-10 mg slowly at a rate of 1 mg/minute, followed by an oral dose of 50 mg 15 minutes later (if no adverse effects result from the inj). Alternatively, repeat an IV dose of 5 mg 10 minutes after the initial doser followed by an oral dose of 50 mg 10 minutes after the last IV dose. A further oral dose of 50 mg may be given 12 hr later. Thereafter, maintain with 50 mg every 12 hr or 100 mg/day for 6-9 days post-MI.
CrCl (ml/min)Dosage Recommendation
15-3510 mg once every 2 days.
<1510 mg once every 4 days.


Special Populations: Renal impairment: CrCl: 15-35 mL/min: 50 mg daily by mouth or 10 mg once every 2 days IV; <15 mL/min: 25 mg daily by mouth or 10 mg once every 4 days IV.
Contraindications
Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.
Warnings / Precautions
Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.
Adverse Reactions
Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.
Potentially Fatal: Heart failure, 2nd or 3rd degree AV block.
Overdose Reactions
Symptoms include lethargy, sinus pause, bradycardia, hypotension, bronchospasm and/or hypoglycaemia. Unabsorbed drug may be removed by induced emesis, gastric lavage or admin of activated charcoal.
Drug Interactions
Decreased effect with aluminum and calcium salts, barbiturates, cholestyramine, NSAIDs, ampicillin, rifampicin.
Potentially Fatal: May increase effects of drugs which slow AV conduction (digoxin, verapamil, diltiazem).
See Below for More atenolol Drug Interactions
Lab Interactions
Increased glucose levels, decreased HDL.
Mechanism of Actions
Atenolol is a competitive cardioselective β1-blocker. It does not have effect on β2-receptors except in high doses. Its cardioselectivity is dose-related. Atenolol reduces resting and exercise-induced heart rate as well as myocardial contractility. Peripheral β-blockade may result in vasoconstriction. Atenolol reduces BP and heart rate which results in reduced myocardial work and O2 requirement leading to improved exercise tolerance and reduced frequency and intensity of anginal attack.
Absorption: Incompletely absorbed from the GI tract (oral); peak plasma concentrations after 1-4 hr.
Distribution: Low lipid solubility, blood-brain barrier (small amounts); crosses the placenta and enters breast milk (concentrations higher than those in plasma). Protein-binding: Minimal.
Metabolism: Hepatic: Minimal.
Excretion: Via urine; elimination half-life: 6-7 hr.
Administration
May be taken with or without food.
Storage Conditions
Intravenous: Store at 20-25°C. Oral: Store at 20-25°C.
ATC Classification
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Storage
Intravenous: Store at 20-25°C. Oral: Store at 20-25°C.
Available As
  • Atenolol 100 mg
  • Atenolol 12.5 mg
  • Atenolol 25 mg
  • Atenolol 5 mg
  • Atenolol 50 mg
  • Atenolol 75 mg
  • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Atenolol


    Drug - Drug Interactions of Atenolol

    We are Developing Our database, More results coming soon.